Stockreport

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

CELGENE  (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
PDF INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today [Read more]